Navigation
Hair Loss News Archives
February 2002
Glaxo says prostate drug safe
LONDON (Reuters) -
Drugs giant GlaxoSmithKline says
late-stage clinical trials show its dutasteride treatment for swollen
prostate glands, one of the most common complaints
in men, is both safe and effective.
A spokesman for Europe's biggest pharmaceutical firm said on Monday the drug had been filed for approval by regulators in both the United States and Europe and should be launched in the second half of this year.
Benign prostate hyperplasia -- or progressive swelling of the prostate gland affects around 75 percent of men over 50.
The condition squeezes and distorts the urethra as it passes through the prostate gland, making it difficult to pass urine.
GlaxoSmithKline said Phase III clinical trials involving over 4,000 patients showed dutasteride had a long-term positive impact on benign prostate hyperplasia compared with placebo.
Analysts at Lehman Brothers forecast peak sales for the drug of around $500 million (350 million pounds) a year by 2009.